

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 September 2025 (12.09.2025)



(10) International Publication Number
WO 2025/186448 A1

- (51) **International Patent Classification:**
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/EP2025/056308
- (22) **International Filing Date:**
07 March 2025 (07.03.2025)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
2403391.2 08 March 2024 (08.03.2024) GB
- (71) **Applicant: MYRICX PHARMA LIMITED** [GB/GB];
125 Wood Street, London EC2V 7AW (GB).
- (72) **Inventors: ZAMMARCHI, Francesca**; c/o MyricX Pharma Limited, 125 Wood Street, London EC2V 7AW (GB).
TOBIN, Jonathan; c/o MyricX Pharma Limited, 125 Wood Street, London EC2V 7AW (GB). **SOLARI, Roberto**; c/o MyricX Pharma Limited, 125 Wood Street, London EC2V 7AW (GB).
- (74) **Agent: TEUTEN, Andrew et al.**; Marlow International, Parkway, Marlow SL7 1YL (GB).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR CONJUGATED TO AN ANTIBODY

(57) **Abstract:** The present invention relates to ADCs comprising a NMT inhibitor conjugated to an antibody via a linker, or a salt thereof, for use in the treatment of cancer in a patient, wherein the cancer is a refractory cancer which shows resistance to treatment with a topoisomerase inhibitor and/or a tubulin inhibitor.



WO 2025/186448 A1